Cargando…

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Detalles Bibliográficos
Autores principales:	Swanson, Chad J., Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y. K., Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A., Berry, Scott, Gordon, Robert, Kramer, Lynn D., Cummings, Jeffrey L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123682/ https://www.ncbi.nlm.nih.gov/pubmed/35598024 http://dx.doi.org/10.1186/s13195-022-00995-9

Ejemplares similares

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
por: Swanson, Chad J., et al.
Publicado: (2021)

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
por: McDade, Eric, et al.
Publicado: (2022)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
por: Dhadda, Shobha, et al.
Publicado: (2022)

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial
por: Berry, Donald A., et al.
Publicado: (2023)

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
por: Logovinsky, Veronika, et al.
Publicado: (2016)

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
por: Hayato, Seiichi, et al.
Publicado: (2022)

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
por: Satlin, Andrew, et al.
Publicado: (2016)

Sensitive detection of Aβ protofibrils by proximity ligation - relevance for Alzheimer's disease
por: Kamali-Moghaddam, Masood, et al.
Publicado: (2010)

Reply: Unblinding in the lecanemab trial in Alzheimer’s disease
por: Hardy, John, et al.
Publicado: (2023)

Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023)

Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ(42) Protofibrils in Alzheimer’s Disease
por: Söllvander, Sofia, et al.
Publicado: (2015)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody
por: Syvänen, Stina, et al.
Publicado: (2018)

Lecanemab reduces brain amyloid-β and delays cognitive worsening
por: Knopman, David S.
Publicado: (2023)

Reply: Lecanemab: turning point, or status quo? An ethics perspective
por: Hardy, John, et al.
Publicado: (2023)

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
por: Wang, Jinping, et al.
Publicado: (2016)

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
por: Jönsson, Linus, et al.
Publicado: (2023)

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death
por: Söllvander, Sofia, et al.
Publicado: (2018)

Amyloid-β Protofibrils: Size, Morphology and Synaptotoxicity of an Engineered Mimic
por: Dubnovitsky, Anatoly, et al.
Publicado: (2013)

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
por: Geerts, Hugo, et al.
Publicado: (2023)

The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023)

Correction: Amyloid-β Protofibrils: Size, Morphology and Synaptotoxicity of an Engineered Mimic
por: Dubnovitsky, Anatoly, et al.
Publicado: (2013)

Amyloid Oligomers and Protofibrils, but Not Filaments, Self-Replicate from Native Lysozyme
por: Mulaj, Mentor, et al.
Publicado: (2014)

The C291R Tau Variant Forms Different Types of Protofibrils
por: Karikari, Thomas K., et al.
Publicado: (2020)

Formation of amyloid loops in brain tissues is controlled by the flexibility of protofibril chains
por: Miller, Alyssa, et al.
Publicado: (2023)

Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils
por: Ekmark-Lewén, S., et al.
Publicado: (2023)

Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
por: Igarashi, Ataru, et al.
Publicado: (2023)

Atomic resolution dynamics on the surface of amyloid β protofibrils probed by solution NMR
por: Fawzi, Nicolas L., et al.
Publicado: (2011)

Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils
por: Groenning, Minna, et al.
Publicado: (2015)

Multiscale Network Modeling of Fibrin Fibers and Fibrin Clots with Protofibril Binding Mechanics
por: Yesudasan, Sumith, et al.
Publicado: (2020)

Protofibril–Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation
por: Hasecke, Filip, et al.
Publicado: (2020)

A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer’s disease
por: Chen, Zu-Lin, et al.
Publicado: (2023)

Fibrin protofibril packing and clot stability are enhanced by extended knob-hole interactions and catch-slip bonds
por: Asquith, Nathan L., et al.
Publicado: (2022)

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
por: Verger, Antoine, et al.
Publicado: (2023)

Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
por: Qiao, Yue, et al.
Publicado: (2023)

Distinct Annular Oligomers Captured along the Assembly and Disassembly Pathways of Transthyretin Amyloid Protofibrils
por: Pires, Ricardo H., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_672vpbm026ibtrm7u591tlruoa